Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA.

Lentz SR, Rodionov RN, Dayal S.

Atheroscler Suppl. 2003 Dec;4(4):61-5. Review.

PMID:
14664904
2.

ADMA and hyperhomocysteinemia.

Dayal S, Lentz SR.

Vasc Med. 2005 Jul;10 Suppl 1:S27-33. Review.

PMID:
16444866
3.

ADMA and oxidative stress.

Sydow K, Münzel T.

Atheroscler Suppl. 2003 Dec;4(4):41-51. Review.

PMID:
14664902
4.

Asymmetric dimethyl-L-arginine (ADMA): a possible link between homocyst(e)ine and endothelial dysfunction.

Stühlinger MC, Stanger O.

Curr Drug Metab. 2005 Feb;6(1):3-14. Review.

PMID:
15720202
6.
7.

Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease.

Ueda S, Yamagishi S, Matsumoto Y, Fukami K, Okuda S.

Clin Exp Nephrol. 2007 Jun;11(2):115-21. Epub 2007 Jun 28. Review.

PMID:
17593510
8.

[Methylarginies-induced endothelial dysfunction in chronic kidney disease].

Kimura K.

Yakugaku Zasshi. 2012;132(4):443-8. Review. Japanese.

9.

Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule.

De Gennaro Colonna V, Bianchi M, Pascale V, Ferrario P, Morelli F, Pascale W, Tomasoni L, Turiel M.

Med Sci Monit. 2009 Apr;15(4):RA91-101. Review.

PMID:
19333216
10.

[Asymmetric dimethylarginine--a novel cardiovascular risk factor].

Siroká R, Cibulka R, Rajdl D, Racek J.

Vnitr Lek. 2006 Mar;52(3):249-55. Review. Czech.

PMID:
16722156
11.

Association of asymmetric dimethylarginine and endothelial dysfunction.

Böger RH.

Clin Chem Lab Med. 2003 Nov;41(11):1467-72. Review.

PMID:
14656027
12.

Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA).

Maas R.

Vasc Med. 2005 Jul;10 Suppl 1:S49-57. Review.

PMID:
16444869
13.

Endothelial cell dysfunction: the syndrome in making.

O'Riordan E, Chen J, Brodsky SV, Smirnova I, Li H, Goligorsky MS.

Kidney Int. 2005 May;67(5):1654-8. Review.

PMID:
15840005
14.

Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA.

Sydow K, Mondon CE, Cooke JP.

Vasc Med. 2005 Jul;10 Suppl 1:S35-43. Review.

PMID:
16444867
15.
16.

ADMA: its role in vascular disease.

Cooke JP.

Vasc Med. 2005 Jul;10 Suppl 1:S11-7. Review.

PMID:
16444864
17.

The clinical significance of asymmetric dimethylarginine.

Siroen MP, Teerlink T, Nijveldt RJ, Prins HA, Richir MC, van Leeuwen PA.

Annu Rev Nutr. 2006;26:203-28. Review.

PMID:
16848705
18.
19.

Asymmetric dimethylarginine: clinical applications in pediatric medicine.

Tain YL, Huang LT.

J Formos Med Assoc. 2011 Feb;110(2):70-7. doi: 10.1016/S0929-6646(11)60012-0. Review.

20.

Asymmetric dimethylarginine as a surrogate marker of endothelial dysfunction and cardiovascular risk in patients with systemic rheumatic diseases.

Dimitroulas T, Sandoo A, Kitas GD.

Int J Mol Sci. 2012 Sep 26;13(10):12315-35. doi: 10.3390/ijms131012315. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk